Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias

Trial Profile

Phase 1B Study of PTC299 in Relapsed/Refractory Acute Leukemias

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PTC 299 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors PTC Therapeutics
  • Most Recent Events

    • 02 Jul 2020 Planned End Date changed from 25 Nov 2020 to 24 Dec 2020.
    • 02 Jul 2020 Planned primary completion date changed from 29 May 2020 to 24 Nov 2020.
    • 26 May 2020 Planned number of patients changed from 36 to 39.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top